Amylyx Pharmaceuticals, Inc. AMLX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Excluding Acquired In Process Cost by Product | ||||||
| AMX0035PSP | $649K-74.6% | $2.56M-14.7% | $3M-58.1% | $7.15M+56.6% | $4.56M+7.5% | |
| Avexitide | $9.99M+49.5% | $6.68M+36.8% | $4.89M-31.2% | $7.11M+30.9% | $5.43M+104% | |
| Other Programs | $7.98M+95.2% | $4.09M+11.9% | $3.65M-7.9% | $3.97M+5.1% | $3.77M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amylyx Pharmaceuticals, Inc. break its business down?
- Amylyx Pharmaceuticals, Inc. (AMLX) reports research and development expense excluding acquired in process cost by product across 3 parts — AMX0035PSP, Avexitide and Other Programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Amylyx Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amylyx Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.